Skip navigation EPAM

Shifting from Insight to Foresight: Welcome to the New Life Sciences Paradigm

George Litos

Principal, Business Consulting, EPAM US

Julie Gorenstein

Manager, Life Sciences Consulting, EPAM US

Chris Waller

VP, Chief Scientist, EPAM US
White Paper
  • Life Sciences

With rising healthcare prices and growing populations, the life sciences industry is under increasing pressure to innovate faster. Better diagnostics and emerging data analytics technologies promise to make this possible, with the goal of predicting outcomes in an automated, systematic manner to answer questions with pinpoint accuracy. For example:

  • Would a novel molecule have better biological activity or availability than the current lead molecule?
  • How would a phenotype change with a modulation within a pathway, or even which node is best to target?
  • Which patients have the highest likelihood of responding to a drug in a clinical trial?
  • Where can a drug have the most impact in improving the overall health of the human population? 

The more data is available, the better the industry can simulate processes in a consistent and logical way, and the faster and cheaper a drug can get to the patient. This white paper explores what needs to happen for life sciences organizations to transition from an insight-driven approach where experimental outcomes are interpreted to a foresight-driven approach where the answer can be predicated before performing experiment design and execution.

Download the white paper for EPAM’s latest thinking on the strategies and technologies that can support this shift to a predictive, foresight-driven R&D paradigm for life sciences. 

Related Content

Boosting Research and Clinical Efficiencies through Master Data Management


Using Intelligent Automation to Create a Healthier Life Sciences Supply Chain


Digital Research Lab Solutions for Life Sciences


Hello. How Can We Help You?

Get in touch with us. We'd love to hear from you.

Our Offices